‘Promising’ durvalumab results spark phase 3 trial in mesothelioma
The median overall survival with durvalumab plus pemetrexed-cisplatin was 20.4 months in patients with treatment-naive, unresectable malignant pleural mesothelioma.
Related Articles
Is It Time to Stop Using the Term AIDS?
AIDS, a term that originated in the early 1980s, does not reflect the current treatment approach, experts suggest.
Can VAP be prevented? New data suggest so
Three RCTs evaluate use of antibiotics in reducing risk of VAP.
Liquid Biopsy Has Near-Perfect Accuracy for Early Pancreatic Cancer
Researchers develop signature for pancreatic cancer based on microRNAs and cell-free DNA markers in the blood of patients with the disease.
Delirium Linked to a Threefold Increased Risk for Dementia
The association, which increased with subsequent episodes of delirium, was strongest in men.
Managing severe asthma exacerbations in the ED: We need answers beyond albuterol
Treatment guidance for severe exacerbations of asthma in the ED is lacking.
A 16-Year-Old Female Presents With Multiple Areas of Hair Loss on the Scalp
A 16-year-old female was referred to the dermatology clinic for evaluation of multiple areas of hair loss on the scalp.
Statins Raise Diabetes Risk, but CV Benefit Outweighs It
An analysis of 23 clinical trials found statins could dose-dependently raise the risk of T2D, but CV improvement was more impactful.
Painful Retiform Purpura in a Peritoneal Dialysis Patient
A 72-year-old woman presented to the emergency department with concerns of confusion and lethargy during a session of peritoneal dialysis, which she had been receiving…
Computer-Aided Colonoscopy Falls Short in Real-World Practice
CADe-assisted colonoscopy has gained increasing attention for its potential to improve adenoma detection rate.
Teen Pregnancy Linked With Risk for Premature Death
“Teen pregnancy may offer an opportunity to intervene in the lives of people at higher risk for premature death.”